Akebia Therapeutics Inc (AKBA)

Jan 07, 2026

Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance

Jan 07, 2026

Jan 07, 2026

Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria

Jan 07, 2026

Jan 06, 2026

Key facts: Akebia starts Phase 2 trial for Praliciguat; grants stock options - TradingView — Track All Markets

Jan 06, 2026

Jan 06, 2026

Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat - marketscreener.com

Jan 06, 2026

Jan 06, 2026

Akebia Therapeutics begins phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa

Jan 06, 2026

Jan 06, 2026

Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire

Jan 06, 2026

Jan 05, 2026

Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Jan 05, 2026

Jan 05, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jan 05, 2026

Jan 05, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 05, 2026

Dec 30, 2025

Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN

Dec 30, 2025

Dec 30, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Dec 30, 2025

Dec 29, 2025

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Quantisnow

Dec 29, 2025

Dec 28, 2025

Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Finviz

Dec 28, 2025

Dec 26, 2025

Dow Update: Can Akebia Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Reactions & Accurate Intraday Trade Tips - moha.gov.vn

Dec 26, 2025

Dec 23, 2025

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN

Dec 23, 2025

Dec 23, 2025

Akebia Therapeutics Earnings Notes - Trefis

Dec 23, 2025

Dec 20, 2025

Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Price Targets & Free Safe Capital Growth Stock Tips - Улправда

Dec 20, 2025

Dec 20, 2025

Why Akebia Therapeutics Inc. (AX9) stock gets analyst attention2025 Performance Recap & Stepwise Trade Signal Implementation - Улправда

Dec 20, 2025

Dec 20, 2025

What insider trading reveals about Akebia Therapeutics Inc. stockTreasury Yields & Accurate Intraday Trade Tips - Улправда

Dec 20, 2025

Dec 20, 2025

Is Akebia Therapeutics Inc. stock a buy for dividend growthPrice Action Analysis & Swing Trade Smarter With Data Insights - Bollywood Helpline

Dec 20, 2025

Dec 20, 2025

Volume Report: Can Akebia Therapeutics Inc. stock outperform in 2025 bull market - Улправда

Dec 20, 2025

Dec 20, 2025

Why Akebia Therapeutics Inc. stock is a must watch in 2025July 2025 Momentum & Fast Moving Market Watchlists - Улправда

Dec 20, 2025

Dec 19, 2025

Is Akebia Therapeutics Inc. stock safe for conservative investorsJuly 2025 Price Swings & Stepwise Swing Trade Plans - Улправда

Dec 19, 2025

Dec 19, 2025

How Akebia Therapeutics Inc. stock performs in weak economyWeekly Trend Summary & Daily Technical Forecast Reports - Улправда

Dec 19, 2025

Dec 19, 2025

Can Akebia Therapeutics Inc. stock deliver sustainable ROEEarnings Overview Report & Expert Curated Trade Setup Alerts - Улправда

Dec 19, 2025

Dec 19, 2025

Why Akebia Therapeutics Inc. stock is considered a top pickGlobal Markets & Free Community Supported Trade Ideas - Bölüm Sonu Canavarı

Dec 19, 2025

Dec 19, 2025

Is Akebia Therapeutics Inc. stock affected by interest rate hikes2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Is Akebia Therapeutics Inc. (AX9) stock considered safe havenJuly 2025 Spike Watch & Accurate Trade Setup Notifications - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Why Akebia Therapeutics Inc. (AX9) stock attracts HNW investorsVolume Spike & Weekly Momentum Stock Picks - Улправда

Dec 19, 2025

Dec 19, 2025

Is Akebia Therapeutics Inc. (AX9) stock a top pick for value investorsMarket Growth Review & Weekly Breakout Stock Alerts - Улправда

Dec 19, 2025

Dec 19, 2025

Will Akebia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Final Week & Community Consensus Trade Signals - Улправда

Dec 19, 2025

Dec 19, 2025

Aug Big Picture: Is Akebia Therapeutics Inc. stock safe for conservative investorsGold Moves & Safe Capital Growth Plans - Улправда

Dec 19, 2025

Dec 19, 2025

Is Akebia Therapeutics Inc. stock a buy on dipsWeekly Profit Recap & Consistent Return Strategy Ideas - Улправда

Dec 19, 2025

Dec 18, 2025

Activity Recap: What insider trading reveals about Akebia Therapeutics Inc. stockLayoff News & Detailed Earnings Play Alerts - Улправда

Dec 18, 2025

Dec 18, 2025

Why analysts recommend Akebia Therapeutics Inc. (AX9) stock2025 Earnings Impact & Advanced Swing Trade Entry Plans - ulpravda.ru

Dec 18, 2025

Dec 18, 2025

Market Moves: Is Akebia Therapeutics Inc. stock a buy on dipsAnalyst Downgrade & Capital Efficiency Focused Ideas - Улправда

Dec 18, 2025

Dec 17, 2025

Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN

Dec 17, 2025

Dec 14, 2025

Akebia Therapeutics (FRA:AX9) OCF Margin % : 47.82% (As of Sep. 2025) - GuruFocus

Dec 14, 2025

Dec 12, 2025

Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN

Dec 12, 2025

Dec 11, 2025

Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance

Dec 11, 2025

Dec 11, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 11, 2025

Dec 06, 2025

Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - moha.gov.vn

Dec 06, 2025

Dec 05, 2025

Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser

Dec 05, 2025

Dec 05, 2025

Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Dec 05, 2025

Dec 04, 2025

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN

Dec 04, 2025

Dec 04, 2025

Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser

Dec 04, 2025

Dec 04, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Dec 04, 2025

Dec 04, 2025

Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals

Dec 04, 2025

Dec 03, 2025

Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights

Dec 03, 2025

Dec 03, 2025

Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat

Dec 03, 2025

Dec 03, 2025

Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat

Dec 03, 2025

Dec 03, 2025

Why Akebia Therapeutics Inc. (AX9) stock could be top winnerQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser

Dec 03, 2025